Research on antibodies and their uses. Covers engineered antitoxin antibodies, long-lasting immunity, monoclonal therapies, and antiviral T cells.
Scientists at Johns Hopkins created a nanoparticle that carries two different antibodies to simultaneously switch off cancer cells' defensive properties while switching on a robust anticancer immune response in mice. The 'immunoswitch' particles dramatically slowed the growth of mouse melanoma and colon cancer, even eradicating tumors.
Researchers from Florida Atlantic University identified 11 cross-reactive terrestrial-specific antibodies for dolphins, allowing them to assess changes in immune cell populations. The study shows significant differences in the absolute number of cells expressing specific markers within lymphocyte and monocyte fractions.
Researchers have discovered a molecular mechanism behind prion protein's role in neurodegenerative diseases, including Creutzfeldt-Jakob and Alzheimer's. The study found that copper biases the prion protein towards its 'off' state, which reduces toxic signals to nerve cells.
Researchers use a redesigned spider venom peptide to deliver biomacromolecules like antibodies into cells, enabling tracking and interaction with target proteins. The technology improves understanding of protein behavior and could lead to new treatments and drug delivery.
AbeXXa Biologics identifies targets for cancer treatment from thousands of intracellular proteins, potentially resulting in effective immunotherapies for broad patient groups. The company is developing T cell receptor-like antibody-drug complexes to kill tumor cells with low peptide/HLA targets.
Researchers at Brigham and Women's Hospital have developed an antibody that can precisely target regulatory T cells, unleashing the immune system to kill cancer cells. The antibody decreased tumor growth in models of melanoma, glioblastoma, and colorectal carcinoma.
Researchers at Stanford University School of Medicine have shown that antibodies to PD-1 and PD-L1 can also prompt immune cells called macrophages to engulf and devour cancer cells, expanding the use of this cancer treatment.
An international team of researchers has identified two receptors on blood vessel cells in the brain that can be blocked to prevent pneumococci from entering. Blocking these receptors with antibodies may lead to a new therapeutic strategy for pneumococcal meningitis.
Scientists at EPFL developed an antibody-linked biosensor that can track drug concentration in the blood by changing color, enabling patients to monitor their treatment levels at home. The biosensor can be adapted to detect virtually unlimited number of molecules.
A team of chemists from Italy and Canada has developed a molecular slingshot made of DNA that can deliver drugs to precise locations in the human body. The device uses a synthetic DNA strand with anchoring moieties that bind to target antibodies, releasing a loaded drug upon recognition.
A research team at Rockefeller University has identified a potent new weapon against the Zika virus: Z004, an antibody that neutralizes the virus and could be used to create a vaccine. The discovery was made by analyzing blood samples from people who had been infected with the virus.
A new study found that desensitizing patient antibodies can reduce the risk of heart transplant rejection in high immunological risk patients. Patients with high levels of anti-HLA antibodies had similar survival rates to those without DSA, but experienced more bleeding complications due to plasmapheresis.
Scientists have discovered clues into how a destructive autoimmune disease works using a unique microscope capable of illuminating living cell structures. They were able to see clusters of antibodies atop astrocytes, the brain cell target of the autoimmune response in neuromyelitis optica.
A team of scientists has discovered an antibody that can measure tau levels in the blood, which accurately reflects brain damage. This breakthrough could lead to a non-invasive test for tau-based diseases, monitoring disease progression, and measuring treatment effectiveness.
MIT researchers have developed a way to make extremely high-resolution images of tissue samples, allowing scientists to see complex patterns in brain synapses and potentially map neural circuits. The new technique uses a tissue-expansion technique to boost resolution to about 25 nanometers.
Engineers at MIT have developed a microfluidic technique to capture and count circulating plasma cells from small samples of blood, potentially providing a less painful test for multiple myeloma. The device uses conventional blood draws and can detect the ratio of different antibodies produced by cancerous and healthy cells.
Researchers have developed a biomarker that can detect early signs of HPV16 E6 antibody presence in blood samples, indicating high risk of developing oropharyngeal cancer. The test is highly specific but not suitable for larger population groups due to low new case incidence rates.
Researchers developed a new treatment pathway removing antibodies from the bloodstream to reduce chronic infections and hospital stays. The approach showed positive outcomes for two patients with resistant Pseudomonas aeruginosa lung infections.
Researchers have developed an effective antibody against radiation-induced pulmonary fibrosis, a debilitating side effect of lung cancer treatment. The antibody targets connective tissue growth factor (CTGF), reversing fibrotic transformation and improving pulmonary function in mice.
A new fluorescent probe developed by Michigan Technological University researchers has the potential to improve cancer surgery outcomes. The probe uses a near-infrared fluorescence that can penetrate deep tissues, reducing background noise and increasing precision for surgeons.
Researchers at Uppsala University have discovered that antibodies against cartilage protein collagen II are associated with a good prognosis in rheumatoid arthritis. The study found that patients with these antibodies showed increased signs of inflammation during the first six months after diagnosis, but no difference later on.
Researchers at Boston Children's Hospital report achieving strong vaccine responses in newborn animals and monkeys using a new adjuvant formulation. The study demonstrates the potential for a single-dose vaccine to protect against life-threatening infections, promising to reduce infant mortality globally.
Researchers developed a new drug delivery method using antibody-drug conjugates (ADCs) that show high precision and stability. The method successfully treated hard-to-treat solid and liquid tumors, including HER2 breast cancer and CD138 multiple myeloma, without harming healthy cells.
A new study found that an antibody targeting CD47 can effectively treat five types of pediatric brain cancer in mice, with no harm to healthy brain cells. The treatment, developed at Stanford, has shown promising results in preclinical trials and is expected to reach clinical trials in children with brain cancer in one to two years.
A lab study identifies mutations in hepatitis C virus that evade the natural immune system and vaccines, highlighting a major barrier to vaccine development. Researchers found that these mutations occur outside of traditional vaccine targets and confer resistance to commonly used antibodies.
Researchers have developed a new method to create antibodies with consistent sugar groups, enhancing their ability to signal the immune system. This breakthrough could lead to more effective therapies for cancer and autoimmune diseases, with the potential for customized antibody production.
Researchers at University of Utah Health Sciences found that a common yeast species exacerbates Inflammatory Bowel Disease (IBD) symptoms in mice. Allopurinol, a generic drug, showed promise in reducing inflammation and potentially offering relief to patients with high yeast antibodies.
A new study reveals that patients with pre-existing donor-specific antibodies experience better kidney survival rates compared to those with de novo antibodies. Understanding the timing of antibody responses can guide matching and prevent rejection.
A Japanese research group has identified a newly-identified autoimmune endocrine disease caused by thymomas, which leads to hypopituitarism. The study found that abnormal expression of PIT-1 in thymoma cells triggers immune tolerance breakdown, resulting in autoimmunity.
By using an antibody-based technique, scientists inactivated GluA1 receptors at synapses, temporarily abolishing fear memory in mice. The researchers found that inactivation of GluA1 up to 2 hours after a fear-learning task resulted in the loss of fear memory.
A team from the University of Pennsylvania identified circulating helper immune cells in blood after an annual flu vaccine, tracking their contribution to antibody strength. The study found that these cells play a crucial role in antibody development and could inform future vaccine design.
A research group at Kobe University has discovered a potential new cancer treatment that activates cancer-engulfing cells. The treatment uses an antibody to activate macrophages, which can effectively eliminate cancer cells. This discovery could lead to the development of new and more effective cancer treatments.
A study at Technical University of Munich found that antibodies can activate human nerve cells within milliseconds, modifying their function. This knowledge improves understanding of illnesses associated with certain types of cancer and paraneoplastic syndromes, which occur when the body's autoimmune reaction attacks its own cells.
A new study found that abnormal antibody production in the intestine of people with HIV-1 may lead to chronic inflammation and AIDS despite treatment. The research revealed that immune system cells in the intestines have decreased capacity to produce mature antibodies.
A study led by NYU Langone researchers identified CD99, a protein-sugar molecule, as a potential therapeutic target for blood stem cell cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Antibodies against CD99 can selectively kill cancer stem cells while sparing normal blood stem cells.
Researchers at UNC have engineered platelets to carry cancer-fighting antibodies, allowing them to target and kill microtumors before they can grow or spread. This innovative approach has shown promising results in animal studies, potentially offering a new hope for patients with recurring cancer after surgery.
A UCF researcher has developed a method that uses nanoparticles and Faraday rotation to measure protein quantities in test solutions, allowing for faster biochemical immunology test results. This technique could lead to faster diagnoses for HIV, Lyme disease, syphilis, and other infectious conditions.
Researchers at UM SOM and SOD published 22 articles on infectious agents, vaccines, and immune system activation. Studies focused on Ebola, Clostridium difficile, biofilms, and other topics, advancing knowledge in infection and immunity research.
Researchers at Uppsala University developed a new antibody design that increases brain uptake of antibodies almost 100-fold, offering new opportunities for treating brain diseases. The modified antibodies use the transferrin receptor to transport them across the blood-brain barrier.
A study found that patients with oropharyngeal cancer who recur have higher levels of antibodies for proteins E6 and E7, which can detect recurrence before it's diagnosed. This biomarker could provide an early window for treatment.
WPI researchers develop a liquid biopsy chip that can trap and identify metastatic cancer cells in small amounts of blood. The device uses antibodies attached to carbon nanotubes, which create an electrical signature that can be detected to identify captured cells.
Researchers at the University of Birmingham found that antibody levels in saliva are linked to those in blood serum, suggesting a non-invasive method for assessing immunity. Higher antibody concentrations in serum were associated with higher concentrations in saliva, particularly for IgA antibodies.
Research shows that blocking type I interferon signaling can enhance the effectiveness of antiretroviral therapy (cART) in HIV-infected mice. By targeting IFN-I signaling, antibodies were able to reduce chronic immune activation and viral load, leading to improved infection management.
Researchers developed a vaccine that stimulates an antibody targeting pathological tau, discovering its Achilles' heel. The antibody avoids immune reaction towards the body by coupling to a carrier molecule.
A new study suggests that blood-borne HPV antibodies can serve as a reliable biomarker for predicting the outcome of all types of head and neck cancer. The researchers found that patients with an immune response to HPV have a lower risk of dying during the five-year follow-up period, regardless of the exact location of their tumors.
ADC MI130110 shows remarkable antitumoral activity in CD13-expressing tumor cells, impairing tubulin polymerization and disrupting the microtubule network. The treatment resulted in significant reduction in tumor size, complete remission, and increased median survival time.
Researchers at Duke University have developed a new PEG delivery system that avoids immune responses and extends the duration of drugs in the bloodstream. The technology, which produces more uniform results, shows excellent efficacy in controlling glucose levels in diabetic mice.
Scientists have created peptide probes that attach to proteins with comparable efficiency to antibodies, improving image resolution. These probes can help shed light on protein layout and quantification, opening new possibilities for neurobiological research.
Researchers at Duke-NUS Medical School have discovered how the human antibody C10 prevents Zika infection by locking proteins into place, preventing viral DNA entry. Disrupting fusion with C10 may be more effective than targeting docking in preventing Zika infection.
Researchers at Georgia Institute of Technology enhance atomic force microscopy by adding electronic white noise to detect molecular interactions in slow motion. This improvement allows for the measurement of varying shades of gray, enabling a more detailed understanding of molecule binding and unbinding.
Researchers found that 2-dose HPV vaccine regimens for girls and boys aged 9-14 years had noninferior antibody responses compared to 3-dose regimens for adolescent girls and young women. The study suggests using a 2-dose schedule could improve adherence to HPV vaccination programs and reduce healthcare costs.
Researchers at UT Austin report that conventional flu vaccines may not be effective, and a new class of antibodies could protect against multiple strains. The study discovered a new approach to identifying and quantifying antibodies in human blood, allowing for more precise understanding of vaccine efficacy.
Antibody drug conjugates (ADCs) have shown efficacy and acceptable toxicity, surpassing radionuclide conjugates in certain tumor types. Targeting cancer stem cells may further improve treatment outcomes.
A 75-million-year-old Mongolian oviraptor fossil preserved the original keratinous claw sheath that covered its digits. The study adds to evidence that organic materials can preserve over time, revealing details about how proteins might be preserved.
A mouse study found an antibody can soothe raging, nerve-driven poison ivy itch by blocking an immune system protein. The researchers also discovered that blocking another receptor for the protein alleviates itch, paving the way for potential treatments.
Researchers have identified a human antibody that prevents Zika virus infection in pregnant mice and protects adult mice. The antibody also prevented damage to the placenta and fetuses, suggesting it may be used to prevent Zika-related birth defects.
Scientists developed two types of llama antibody that can specifically mark and show amyloid plaques and neurofibrillary tangles, the characteristic lesions of Alzheimer's disease. These antibodies have the rare ability to cross the blood-brain barrier, allowing for non-invasive detection.
Researchers found that the key viral protein used in candidate HCV vaccines is surprisingly flexible, elicit a wide variety of antibodies that cannot block viral infection. This flexibility may be why current vaccines have been ineffective in preventing HCV infection.
Scientists at the University of Basel discovered that chronic viral infections lead to an inadequate immune response due to prolonged inflammation. This hasty reaction by B cells produces antibodies quickly but also leads to their rapid depletion, resulting in a short-lived and unsustainable defense against the virus.
Three different candidate Zika vaccines have been found to protect rhesus monkeys against the disease in trials. The vaccines, tested in preclinical trials, were found to be effective at warding off infection by the Zika virus strain circulating in Brazil and Puerto Rico.